The release of the snapshot containing the respective simulations can be found here:
https://github.com/Open-Systems-Pharmacology/Rifampicin-Alprazolam-DDI/releases/tag/v1.2

The rifampicin-alprazolam interaction was evaluated using two clinical DDI studies quantifying the interaction in three clinical settings ([Gashaw 2003](#4-references), [Schmider 1999](#4-references)).



| DataID | Enzyme | Perpetrator / victim    | Study design                                                 | Comments                                                     | Clinical study                 |
| ------ | ------ | ----------------------- | ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------------ |
| 2009   | CYP3A4 | Rifampicin / alprazolam | Rifampicin: 450 mg, five doses at irregular times intervals over 4 days<br />Alprazolam: 1 mg po single dose, 14 hours after the last rifampicin dose |                                                              | [Gashaw 2003](#4-references)   |
| 2010   | CYP3A4 | Rifampicin / alprazolam | Rifampicin: 450 mg, five doses at irregular times intervals over 4 days followed by a wash-out phase for 14 days<br />Alprazolam: 1 mg po single dose after the wash-out phase (i.e. 350 hours after the last rifampicin dose) |                                                              | [Gashaw 2003](#4-references)   |
| 1001   | CYP3A4 | Rifampicin / alprazolam | Rifampicin: 450 mg po QD for 4 days<br />Alprazolam: 1 mg po single dose, 24 hours after the last rifampicin dose | Administration time of alprazolam relative to rifampin not reported; it was assumed that alprazolam was administered 24h after the last rifampin dose | [Schmider 1999](#4-references) |


